Contact pathway of coagulation and inflammation

Thrombosis Journal

Yi Wu¹ 

[1] The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3420 N. Broad Street, Philadelphia 19140, PA, USA

关键词: Vascular biology;    Autoimmune disease;    Infection;    Platelet;    Inflammation;    Coagulation;    Contact system;   

Others  :  1194948
DOI  :  10.1186/s12959-015-0048-y

 received in 2014-10-23, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor high molecular weight kininogen (HK). This system has been investigated actively for more than 50 years. The components of this system and their interactions have been elucidated from in vitro experiments, which indicates that this system is prothrombotic by activating intrinsic pathway, and proinflammatory by producing bioactive peptide bradykinin. Although the activation of the contact system have been implicated in various types of human disease, in only a few instances is its role clearly defined. In the last 10 years, our understanding of the contact system, particularly its biology and (patho)physiology has greatly increased through investigations using gene-modified animal models. In this review we will describe a revitalized view of the contact system as a critical (patho)physiologic mediator of coagulation and inflammation.

【 授权许可】

   
2015 Wu; licensee BioMed Central.

【 参考文献 】

• [1]Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997; 90(10):3819-43.
• [2]Colman RW, Sartor RB, Adam AA, DeLa Cadena RA, Stadnicki A. The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol. 1998; 16(4):365-84.
• [3]Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009; 7(3):234-50.
• [4]Yang A, Dai J, Xie Z, Colman RW, Wu Q, Birge RB et al.. High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis. J Immunol. 2014; 192(9):4398-408.
• [5]Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost. 2011; 37(4):375-81.
• [6]Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM et al.. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009; 139(6):1143-56.
• [7]Azevedo C, Saiardi A. Functions of inorganic polyphosphates in eukaryotic cells: a coat of many colours. Biochem Soc Trans. 2014; 42(1):98-102.
• [8]Caen J, Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost. 2010; 8(8):1670-4.
• [9]Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest. 2008; 118(9):3006-9.
• [10]van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ et al.. Dual role of collagen in factor XII-dependent thrombus formation. Blood. 2009; 114(4):881-90.
• [11]Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S et al.. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011; 17(2):206-10.
• [12]Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett. 2001; 500(1–2):36-40.
• [13]Saito A, Munakata H. Analysis of plasma proteins that bind to glycosaminoglycans. Biochim Biophys Acta Gen Subj. 2007; 1770(2):241-6.
• [14]Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost. 2010; 104(5):875-85.
• [15]Wu Y, Rizzo V, Liu Y, Sainz IM, Schmuckler NG, Colman RW. Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2007; 27(9):1968-75.
• [16]Khan MM, Bradford HN, Isordia-Salas I, Liu Y, Wu Y, Espinola RG et al.. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler Thromb Vasc Biol. 2006; 26(10):2260-6.
• [17]Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol. 2005; 175(5):3377-85.
• [18]Ben Nasr A, Olsén A, Sjöbring U, Müller-Esterl W, Björck L. Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Mol Microbiol. 1996; 20(5):927-35.
• [19]Ben Nasr A, Herwald H, Sjobring U, Renne T, Muller-Esterl W, Bjorck L. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin. The Biochemical J. 1997; 326(Pt 3):657-60.
• [20]Gershom ES, Sutherland MR, Lollar P, Pryzdial ELG. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost. 2010; 8(5):1037-43.
• [21]Mitropoulos KA, Reeves BE, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coagul Fibrinolysis. 1993; 4(2):223-34.
• [22]von dem Borne PA, Cox LM, Bouma BN. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor. Blood Coagul Fibrinolysis. 2006; 17(4):251-7.
• [23]Colman RW. Contributions of Mayme Williams to the elucidation of the multiple functions of plasma kininogens. Thromb Haemost. 1992; 68(2):99-101.
• [24]Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P et al.. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005; 202(2):271-81.
• [25]Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P et al.. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006; 203(3):513-8.
• [26]Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF et al.. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010; 116(19):3981-9.
• [27]Renne T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis. 2006; 36(2):148-51.
• [28]Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP et al.. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait. Thromb Haemost. 2012; 107(6):1141-50.
• [29]Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C et al.. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011; 118(19):5302-11.
• [30]Merkulov S, Zhang WM, Komar AA, Schmaier AH, Barnes E, Zhou Y et al.. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008; 111(3):1274-81.
• [31]Langhauser F, Gob E, Kraft P, Geis C, Schmitt J, Brede M et al.. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood. 2012; 120(19):4082-92.
• [32]Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012; 10(7):1355-62.
• [33]Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102–7.
• [34]von Brühl M-L, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M et al.. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012; 209(4):819-35.
• [35]Oehmcke S, Mörgelin M, Herwald H. Activation of the Human Contact System on Neutrophil Extracellular Traps. J Innate Immun. 2009; 1(3):225-30.
• [36]Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J et al.. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009; 206(11):2381-95.
• [37]Xu Y, Cai TQ, Castriota G, Zhou Y, Hoos L, Jochnowitz N et al.. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost. 2014; 111(4):694-704.
• [38]Levi M, Hack CE, de Boer JP, Brandjes DP, ller HR et al.. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest. 1991; 88(4):1155-60.
• [39]Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI Deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991; 325(3):153-8.
• [40]Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC et al.. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Investig. 1998; 101(1):10-4.
• [41]Frick I-M, Björck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost. 2007; 98(9):497-502.
• [42]Scharfstein J, Andrade D, Svensjö E, Oliveira AC, Nascimento CR. The Kallikrein-Kinin-System in Experimental Chagas Disease: A Paradigm to Investigate the Impact of Inflammatory Edema on GPCR-mediated pathways of Host Cell Invasion by Trypanosoma cruzi. Frontiers Immunol. 2013; 3:396.
• [43]Frick IM, Åkesson P, Herwald H, Mörgelin M, Malmsten M, Nägler DK, et al. The contact system—a novel branch of innate immunity generating antibacterial peptides. EMBO J. 2006;25(23):5569-78.
• [44]Imamura T, Potempa J, Pike RN, Travis J. Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis. Infect Immun. 1995; 63(5):1999-2003.
• [45]Scharfstein J, Andrade D, Svensjö E, Oliveira AC, Nascimento CR. The Kallikrein-Kinin-System in Experimental Chagas Disease: A Paradigm to Investigate the Impact of Inflammatory Edema on GPCR-mediated pathways of Host Cell Invasion by Trypanosoma cruzi. Frontiers Immunol. 2013;3:396.
• [46]Fein AM, Bernard GR, Criner GJ et al.. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (cp-0127): results of a randomized, double-blind, placebo-controlled trial. JAMA. 1997; 277(6):482-7.
• [47]Lima APCA, Almeida PC, Tersariol ILS, Schmitz V, Schmaier AH, Juliano L et al.. Heparan sulfate modulates kinin release by trypanosoma cruzi through the activity of cruzipain. J Biol Chem. 2002; 277(8):5875-81.
• [48]Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. PLoS Pathog. 2013; 9(7):e1003470.
• [49]DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, Back N, et al. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol. 1991;260(2 Pt 1):G213–9.
• [50]Sainz IM, Isordia-Salas I, Castaneda JL, Agelan A, Liu B, DeLa Cadena RA et al.. Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum. 2005; 52(8):2549-52.
• [51]Dai J, Agelan A, Yang A, Zuluaga V, Sexton D, Colman RW et al.. Role of plasma kallikrein-kinin system activation in synovial recruitment of endothelial progenitor cells in experimental arthritis. Arthritis Rheum. 2012; 64(11):3574-82.
• [52]Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH et al.. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest. 2011; 121(9):3517-27.
• [53]Xie Z, Dai J, Yang A, Wu Y. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. Rheumatology (Oxford). 2014; 53(7):1301-6.
• [54]Szekanecz Z, Besenyei T, Szentpétery Á, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2010; 22(3):299-306.
• [55]Thairu N, Kiriakidis S, Dawson P, Paleolog E. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis. 2011; 14(3):223-34.
• [56]Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE. The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum. 2007; 56(6):1817-26.
• [57]Ruger B, Giurea A, Wanivenhaus AH, Zehetgruber H, Hollemann D, Yanagida G et al.. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2004; 50(7):2157-66.
• [58]Wu Y, Dai J, Schmuckler NG, Bakdash N, Yoder MC, Overall CM et al.. Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2. J Thromb Haemost. 2010; 8(1):185-93.
• [59]Dai J, Zhu X, Yoder MC, Wu Y, Colman RW. Cleaved high-molecular-weight kininogen accelerates the onset of endothelial progenitor cell senescence by induction of reactive oxygen species. Arterioscler Thromb Vasc Biol. 2011; 31(4):883-9.
• [60]Devani M, Cugno M, Vecchi M, Ferrero S, Di Berardino F, Avesani EC et al.. Kallikrein-kinin system activation in Crohn’s disease: differences in intestinal and systemic markers. Am J Gastroenterol. 2002; 97(8):2026-32.
• [61]Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;289(2):G361-6.
• [62]Stadnicki A, Sartor RB, Janardham R, Stadnicka I, Adam AA, Blais C et al.. Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats. Gut. 1998; 43(3):365-74.
• [63]Isordia-Salas I, Pixley RA, Li F, Sainz I, Sartor RB, Adam A et al.. Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol. 2002; 283(1):G180-6.
• [64]Hara DB, Leite DFP, Fernandes ES, Passos GF, Guimarães AO, Pesquero JB et al.. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol. 2008; 154(6):1276-86.
• [65]Lu F, Fernandes SM, Davis AE. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G878–83.